logo-loader
RNS
viewHemoGenyx Pharmaceuticals

Total Voting Rights

/**/ .ag{size:612.0pt 792.0pt;margin:72.0pt 72.0pt 72.0pt 72.0pt;}div.ag{}p.a,li.a,div.a{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Calibri","sans-serif";}p.bf{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";text-align: center}span.bg{color: black; font-size: 11.0pt; font-weight: bold}p.bh{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Calibri","sans-serif";text-align:justify}span.bb{font-size:11.0pt;font-family:"Times New Roman","serif";color:black}p.bi{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";text-align:justify}span.az{font-size:11.0pt; color:black}span.ad{} span.bj{font-size:11.0pt;font-family:"Times New Roman","serif"; color:black}span.bk{font-size:11.0pt; font-family:"Times New Roman","serif";color:black}span.bl{font-family:"Times New Roman","serif"}span.bm{font-size:11.0pt;font-family:"Times New Roman","serif";color:black}p.bn{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Calibri","sans-serif";font-weight: bold; line-height: 11.75pt; margin-bottom: 12.1pt; text-align: justify}span.ay{font-size:11.0pt;font-family:"Times New Roman","serif"; color:black}table.bo{width:15.0cm;margin-left:-10.8pt;border-collapse:collapse}td.au{width:261.9pt;padding:0cm 5.4pt 0cm 5.4pt}td.as{width:120.15pt;padding:0cm 5.4pt 0cm 5.4pt}p.bp{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Calibri","sans-serif";margin-bottom:12.1pt;line-height:11.75pt} p.bq{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Calibri","sans-serif";margin-bottom:12.1pt;text-align:justify;line-height: 11.75pt}p.br{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Calibri","sans-serif";font-div: italic; line-height: 11.75pt; margin-bottom: 12.1pt}p.bs{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Calibri","sans-serif";font-weight: bold; line-height: 11.75pt; margin-bottom: 12.1pt}tr.am{height:7.3pt}td.ao{width:261.9pt;padding:0cm 5.4pt 0cm 5.4pt; height:7.3pt}td.an{width:120.15pt;padding:0cm 5.4pt 0cm 5.4pt; height:7.3pt}span.ak{font-size:11.0pt;font-family:"Times New Roman","serif"}span.aj{font-size:11.0pt;font-family:"Times New Roman","serif"; color:#14171A}p.bt{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";text-align:justify}span.bu{color: black; font-size: 11.0pt; font-weight: bold; text-decoration: underline} p.bv{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";text-align:justify}span.bw{font-size:11.0pt;color:black} /**/
RNS Number : 4102H
Hemogenyx Pharmaceuticals PLC
01 August 2019
 

 

 

 

Hemogenyx Pharmaceuticals plc

("Hemogenyx" or the "Company")

 

Total Voting Rights

 

 

Hemogenyx Pharmaceuticals plc (LSE: HEMO) announces, for the purposes of the FCA's Disclosure Guidance and Transparency Rules, that the total issued share capital of the Company consists of 361,242,853 ordinary shares of 0.01p each with voting rights.  This figure may be used by shareholders in the Company as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company.

Further to the announcement made on 3 July 2019, an application has been made to the London Stock Exchange Main Market for the admission of 4,133,330 new ordinary shares to trading, which is expected on or around 9 August 2019.  These new shares relate to an allotment of 4,008,504 ordinary shares to Cornell University announced on 5 October 2017 in partial satisfaction of a licence fee and 124,826 ordinary shares that were issued following an exercise of warrants on 30 May 2018. 

 

 

Enquiries:

Hemogenyx Pharmaceuticals plc

www.hemogenyx.com

Dr Vladislav Sandler, Chief Executive Officer & Co-Founder

[email protected]

Sir Marc Feldmann, Executive Chairman




SP Angel Corporate Finance LLP

Tel: +44 (0)20 3470 0470

Matthew Johnson, Vadim Alexandre, Soltan Tagiev




Peterhouse Corporate Finance Limited

Tel: +44 (0)20 7469 0930

Lucy Williams, Duncan Vasey




US Media enquiries

Tel: +1 (323) 646-3249

Lowell Goodman

[email protected]

 

 

About Hemogenyx Pharmaceuticals plc

Hemogenyx Pharmaceuticals plc ("Hemogenyx") is a publicly traded company (LSE: HEMO) headquartered in London, with its wholly-owned US operating subsidiaries, Hemogenyx LLC and Immugenyx LLC, located at its state-of-the-art research facility in New York City and a wholly-owned Belgian operating subsidiary, Hemogenyx-Cell SPRL, located in Liège.

Hemogenyx is a pre-clinical stage biopharmaceutical group developing new medicines and treatments to bring the curative power of bone marrow transplantation to a greater number of patients suffering from otherwise incurable life-threatening diseases. Hemogenyx is developing two distinct and complementary products, as well as a platform technology that it uses as an engine for novel product development.

For more than 50 years, bone marrow transplantation has been used to save the lives of patients suffering from blood diseases. The risks of toxicity and death that are associated with bone marrow transplantation, however, have meant that the procedure is restricted to use only as a last resort. Hemogenyx's technology has the potential to enable many more patients suffering from devastating blood diseases such as leukemia and lymphoma, as well as severe autoimmune diseases such as multiple sclerosis, aplastic anemia and systemic lupus erythematosus (Lupus), to benefit from bone marrow transplantation.


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
TVREAAXFDEFNEFF

Quick facts: HemoGenyx Pharmaceuticals

Price: 2

Market: LSE
Market Cap: £7.22 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

HemoGenyx CEO 'overwhelmed' by speed of progress at the company

Dr Vladislav Sandler, chief executive of HemoGenyx Pharmaceuticals PLC (LON:HEMO), caught up with Proactive's Andrew Scott while in London to meet with investors. It's been nearly nine months now since the company first listed in London and in that time they've inked four collaborations...

on 27/6/18